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BACKGROUND
Tuberculosis regimens that are shorter and simpler than the current 6-month daily 
regimen are needed.
METHODS
We randomly assigned patients with newly diagnosed, smear-positive, drug-sensitive 
tuberculosis to one of three regimens: a control regimen that included 2 months 
of ethambutol, isoniazid, rifampicin, and pyrazinamide administered daily followed 
by 4 months of daily isoniazid and rifampicin; a 4-month regimen in which the iso-
niazid in the control regimen was replaced by moxifloxacin administered daily for 
2 months followed by moxifloxacin and 900 mg of rifapentine administered twice 
weekly for 2 months; or a 6-month regimen in which isoniazid was replaced by 
daily moxifloxacin for 2 months followed by one weekly dose of both moxifloxacin 
and 1200 mg of rifapentine for 4 months. Sputum specimens were examined on 
microscopy and after culture at regular intervals. The primary end point was a 
composite treatment failure and relapse, with noninferiority based on a margin of 
6 percentage points and 90% confidence intervals.
RESULTS
We enrolled a total of 827 patients from South Africa, Zimbabwe, Botswana, and 
Zambia; 28% of patients were coinfected with the human immunodefiency virus. 
In the per-protocol analysis, the proportion of patients with an unfavorable response 
was 4.9% in the control group, 3.2% in the 6-month group (adjusted difference from 
control, −1.8 percentage points; 90% confidence interval [CI], −6.1 to 2.4), and 18.2% 
in the 4-month group (adjusted difference from control, 13.6 percentage points; 
90% CI, 8.1 to 19.1). In the modified intention-to-treat analysis these proportions 
were 14.4% in the control group, 13.7% in the 6-month group (adjusted difference 
from control, 0.4 percentage points; 90% CI, −4.7 to 5.6), and 26.9% in the 4-month 
group (adjusted difference from control, 13.1 percentage points; 90% CI, 6.8 to 19.4).
CONCLUSIONS
The 6-month regimen that included weekly administration of high-dose rifapentine 
and moxifloxacin was as effective as the control regimen. The 4-month regimen was 
not noninferior to the control regimen. (Funded by the European and Developing 
Countries Clinical Trials Partnership and the Wellcome Trust; RIFAQUIN Current 
Controlled Trials number, ISRCTN44153044.)
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Effective 6-month chemotherapy regimens for the treatment of pulmonary tuberculosis have been evaluated in nu-
merous controlled trials. When adequately ad-
ministered, they are capable of achieving re-
lapse-free cure rates of 95% or more in patients 
infected by drug-sensitive organisms.1,2 Howev-
er, there is a need to investigate regimens that 
could improve operational cure rates by shorten-
ing or simplifying treatment. Previous attempts 
in which intermittent dosing of rifapentine was 
used3 have resulted in unacceptable relapse rates4,5 
and, in patients coinfected with the human im-
munodeficiency virus (HIV), acquired resistance 
to rifamycin.6 Studies in mice suggest that com-
bining high-dose rifapentine with moxifloxacin 
may improve cure rates.7,8 The objectives of this 
trial were to assess whether regimens of 6 months’ 
or 4 months’ duration that included a continua-
tion phase of intermittent treatment with rifa-
pentine and moxifloxacin were not inferior to 
the standard 6-month regimen based on daily 
dosing of isoniazid and rifampicin and were able 
to prevent acquired resistance to rifamycin in re-
lapsing patients who were coinfected with HIV.
Me thods
Study Oversight
This international, multicenter, randomized, con-
trolled trial was carried out within the framework 
of the International Consortium for Trials of Che-
motherapeutic Agents in Tuberculosis (INTERTB). 
The trial was sponsored and implemented by St. 
George’s, University of London, together with the 
Medical Research Council Clinical Trials Unit 
(MRC CTU) at University College London and six 
institutions in southern Africa. The study protocol 
(available with the full text of this article at NEJM 
.org) was reviewed and approved by the ethics 
review committee at St. George’s by medical eth-
ics and regulatory committees representing each 
of the participating countries, and by the insti-
tutional review board of the Centers for Disease 
Control and Prevention operating in Botswana. 
An independent data and safety monitoring com-
mittee reviewed study data at intervals of approxi-
mately 6 months throughout the study.
Patients
To participate in the trial, patients had to provide 
written informed consent, to be older than 18 
years of age, to weigh 35 kg or more, to provide 
two sputum samples that were positive for tubercle 
bacilli on direct smear microscopy, to have had 
less than a month of previous anti-tuberculosis 
chemotherapy, and to have a firm home address 
that was readily accessible for visiting. Participants 
were also expected to survive the initial weeks of 
treatment. Patients coinfected with HIV who re-
quired antiretroviral therapy (ART) at diagnosis 
were initially ineligible; as the trial progressed, 
persons starting ART at screening were deemed 
eligible. Persons with a CD4 cell count of less 
than 200 per cubic millimeter were initially in-
eligible, but this number was subsequently amend-
ed to 150 per cubic millimeter.3
To minimize the risk of the development of 
multidrug or polydrug resistance and of relapses 
caused by acquired resistance to rifamycin, pa-
tients who had resistance to isoniazid, rifampicin, 
or moxifloxacin were excluded. In most instanc-
es this determination could not be made until 
after randomization. A complete list of eligibil-
ity criteria is provided in the Supplementary Ap-
pendix, available at NEJM.org.
After counseling, patients were tested for HIV. 
The result was disclosed to the patient unless 
otherwise requested, except in Botswana, where 
disclosure is mandatory. Post-test counseling was 
given to all persons who were tested, and those 
who were infected with HIV were given clinical 
care within their health service, in accordance 
with local practice. Chest radiographs were ob-
tained at baseline and evaluated by an experi-
enced assessor to determine the radiographic 
extent of disease and the presence or absence of 
cavitation.9,10
Study Design
A randomized allocation sequence was generated 
for each study center with the use of blocks of 
varying size by an independent statistician based 
at the MRC CTU. Apart from the statisticians 
reporting to the data and safety monitoring com-
mittee, the staff at St. George’s and at the MRC 
CTU were unaware of treatment assignment ex-
cept when a lack of awareness would have been 
unethical (e.g., in some discussions of serious 
adverse events). Participating laboratories were 
unaware of treatment assignment throughout the 
study.
Eligible patients who had provided written 
informed consent were randomly assigned in a 
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ratio of 1:1:1 to one of three regimens: a control 
regimen, which consisted of 6 months of isonia-
zid and rifampicin administered daily, supple-
mented by ethambutol and pyrazinamide in the 
first 2 months; a 4-month regimen, which con-
sisted of 2 months of ethambutol, moxifloxacin 
(400 mg), rifampicin, and pyrazinamide admin-
istered daily, followed by 2 months of moxi-
floxacin and rifapentine (900 mg) administered 
twice weekly; and a 6-month regimen, which 
consisted of 2 months of ethambutol, moxifloxa-
cin (400 mg), rifampicin, and pyrazinamide ad-
ministered daily, followed by 4 months of moxi-
floxacin and rifapentine (1200 mg) administered 
weekly. All drugs were administered at standard 
doses11 unless otherwise stated; further details 
are provided in the Supplementary Appendix. 
Some of the trial medications were donated by 
Sanofi, Genus Pharmaceuticals, and Sandoz, and 
a representative of Sanofi was a nonvoting ob-
server at meetings of the steering committee, but 
none of these companies had any role in the study 
design, data accrual, data analysis, or manuscript 
preparation. Because rifapentine absorption is 
improved when administered with a meal,12 each 
dose of rifapentine was preceded by a meal of 
two hard-boiled eggs and bread. Treatment was 
directly observed at the health facility except 
during the daily continuation phase of the control 
regimen, during which treatment was supervised 
by a relative or another person.
Under the conditions of the trial, the standard 
6-month regimen has a 95% or higher success 
rate.1,2 For this reason, the study was designed to 
determine whether either of the experimental 
regimens was not inferior to the control regimen 
when a margin of noninferiority of 6 percentage 
points was used. The target sample size was 1095; 
it was calculated with the use of a two-sided 
90% confidence interval to achieve 80% power. 
Details of the calculations are provided in the 
Supplementary Appendix.
Efficacy and Safety
Two sputum samples were collected for smears 
and culture before treatment, and one sample was 
collected monthly for 12 months and then again 
at 15 months and 18 months. Samples from cen-
ters in Zimbabwe were cultured on Löwenstein–
Jensen solid medium and samples from centers 
in South Africa and Botswana were cultured in 
liquid medium in a Mycobacteria Growth Indica-
tor Tube. Cultures in Zambia were done on both 
media. Adverse events were graded for severity 
with the use of criteria from the National Insti-
tute of Allergy and Infectious Diseases, Division 
of AIDS, after a minor modification.13 Most pa-
tients (86%) were followed for 18 months from 
randomization. However, patients in South Africa 
and Botswana who underwent randomization in 
the final 6-month period of enrollment had a 
reduced follow-up period (either 12 months or 
15 months) to permit prolongation of the enroll-
ment period (see the Supplementary Appendix).
The primary efficacy end point was the pro-
portion of patients with an unfavorable outcome, 
defined as any of the following outcomes: a re-
start or change of treatment for any reason 
other than making up for missed doses or be-
coming pregnant, a positive culture from sam-
ples obtained at the most recent follow-up visit, 
death before the end of scheduled treatment for 
reasons other than violence or trauma, death after 
the end of treatment with evidence that confirmed 
or suggested possible treatment failure or relapse 
of their tuberculosis, and failure to complete treat-
ment without a negative culture result at the end 
of the scheduled follow-up period. Relapse after 
completion of treatment was defined as two posi-
tive cultures within a period of 4 months without 
an intervening negative culture (as in earlier tu-
berculosis trials2) and without genotypic evidence 
of reinfection. A favorable outcome was defined 
as having a negative culture at the scheduled end 
of follow-up and not having had an outcome that 
had already been classified as unfavorable. This 
definition is consistent with definitions used in 
several other phase 3 tuberculosis trials.1,14,15 More 
detail is provided in the Supplementary Appendix.
For all treatment failures and relapses, one 
culture of a sputum sample obtained before treat-
ment and one culture of a sputum sample obtained 
after treatment failure or relapse were stored at 
−20°C and the samples were sent to the Depart-
ment of Medical Microbiology at St. George’s for 
culture and susceptibility testing. Heat-killed or-
ganisms were transferred to the Centre for Clini-
cal Microbiology, University College London, for 
DNA extraction and genotyping by means of my-
cobacterial interspersed repetitive unit–variable-
number tandem repeats (MIRU-VNTRs).16 Patients 
with a reinfection that was defined as a difference 
of at least two MIRU loci were excluded from the 
analysis.
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At each study center, two designated data-
entry persons entered case-report forms into a 
bespoke database developed by the MRC CTU. 
Data files were transmitted electronically, at regu-
lar intervals, to the MRC CTU.
Statistical Analysis
In accordance with the standard approach to the 
analysis of noninferiority trials,17 the analysis was 
conducted with both per-protocol and modified 
intention-to-treat populations. Noninferiority must 
be shown on both analyses to declare that either 
regimen is noninferior. The absolute difference 
in the proportion of unfavorable outcomes was 
calculated by means of a generalized linear model 
with an identity-link function. Noninferiority was 
assessed with the use of the upper bound of the 
two-sided 90% Wald confidence interval (which 
is equivalent to a one-sided significance of 5%), 
and the results were adjusted for study center. 
One-sided tests are appropriate for noninferior-
ity trials,18 and a one-sided significance level of 
5% has been used in previous noninferiority trials 
involving tuberculosis.1,14 No adjustment was made 
for multiple comparisons since each regimen 
was designed to address different questions. This 
approach is consistent with expert opinion.19-22
Prespecified subgroup analyses were conduct-
ed according to HIV status and study center, but 
results are reported only for analyses made ac-
cording to HIV status because no heterogeneity 
was found in analyses conducted according to 
center. The analysis of culture results at 2 months 
was limited to participants for whom sputum 
samples were collected between 6 and 10 weeks 
after randomization. If more than one culture 
result was available during this time period, a 
positive result took precedence over a negative 
result. All analyses were conducted with the use 
of STATA software, version 12.1 (Stata). Full de-
tails of the analysis strategy are in the Supple-
mentary Appendix.
R esult s
Study Population
Between August 15, 2008, and August 1, 2011, a 
total of 827 patients were enrolled at centers in 
Worcester (209) and Johannesburg (255), South 
Africa, in Harare (203) and Marondera (89), Zim-
babwe, in Francistown, Botswana (56), and in 
Macha, Zambia (15). A total of 97 late screening 
failures were excluded from the primary efficacy 
analysis; in the majority of these cases, cultures 
obtained at baseline were either not positive or 
showed the presence of drug-resistant strains. A 
total of 593 and 514 patients were included in 
the modified intention-to-treat and per-protocol 
analyses, respectively (see the Consolidated Stan-
dards for the Reporting of Trials [CONSORT] 
diagram in Fig. 1 for details on reasons for study 
exclusion). The baseline characteristics of par-
ticipants were similar across all three regimens 
(Table 1).
Efficacy
The proportion of patients with unfavorable out-
comes among those receiving the control regi-
men, the 4-month regimen, and the 6-month 
regimen was 4.9%, 18.2%, and 3.2%, respectively, 
in the per-protocol analysis, and 14.4%, 26.9% 
and 13.7%, respectively, in the modified inten-
tion-to-treat analysis (Table 2). The site-adjusted 
difference in the proportion of unfavorable out-
comes between patients receiving the 4-month 
regimen and those receiving the control regimen 
was 13.1 percentage points (90% confidence 
interval [CI], 6.8 to 19.4) in the modified inten-
tion-to-treat analysis and 13.6% (90% CI, 8.1 to 
19.1) in the per-protocol analysis. In both analyses, 
the 4-month regimen was inferior to the control 
regimen, since the lower bound of the 90% con-
fidence interval was greater than 6 percentage 
points, although identifying a regimen as infe-
rior was not a prespecified objective of the trial.
The site-adjusted difference in the proportion 
of unfavorable outcomes between the 6-month 
regimen and the control regimen was 0.4 per-
centage points (90% CI, −4.7 to 5.6) in the modi-
fied intention-to-treat analysis and −1.8 percentage 
points (90% CI, −6.1 to 2.4) in the per-protocol 
analysis. In both analyses, the upper bound of 
the prespecified primary 90% confidence inter-
vals was less than the margin of noninferiority 
of 6 percentage points, showing that the 6-month 
regimen was noninferior to control regimen 
when a one-sided significance level of 5% was 
used. Although the stricter 95% confidence in-
terval for the per-protocol analysis gives a con-
sistent interpretation, the 95% confidence inter-
val for the modified intention-to-treat analysis 
does not show noninferiority (Table 2). Testing 
the one-sided null hypothesis that this differ-
ence was greater or equal to 6 percentage points 
produced a P value of 0.04 for the modified in-
tention-to-treat analysis and a P value of 0.001 
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Figure 1. Screening, Randomization, and Analysis of the Study Populations.
Among the patients who did not undergo randomization, there were 17 patients who did not do so for other rea-
sons: 4 patients had a history of seizures, 4 did not return in order to undergo randomization, 3 weighed less than 
35 kg, 1 had extra-pulmonary tuberculosis, 1 had no firm address, 1 was younger than 18 years of age, 1 was receiv-
ing antiretroviral therapy, and 1 had tachycardia. In addition, there was 1 patient in whom attempts to draw blood 
were unsuccessful. MIRU–VNTRS denotes mycobacterial interspersed repetitive unit–variable-number tandem re-
peats, and TB tuberculosis.
827 Underwent randomization
1099 Patients were assessed for eligibility
272 (25%) Were excluded
194 (71%) Had CD4 count <200/mm3
15 Had inadmissible blood chemistry
results
13 Had glycosuria
10 Had more than 14 days of previous TB
treatment
9 Withdrew consent
7 Were pregnant or breast-feeding
7 Had negative smear
17 Had other reason
275 Were assigned to receive
control regimen
277 Were assigned to receive
6-mo regimen
240 Were eligible for the study
35 (13%) Were late exclusions
22 Did not have culture confirmation
of TB
12 Had initial drug resistance
1 Had previous treatment for TB
251 Were eligible for the study
26 (9%) Were late exclusions
13 Did not have culture confirmation
of TB
13 Had initial drug resistance
275 Were assigned to receive
4-mo regimen
239 Were eligible for the study
36 (13%) Were late exclusions
20 Did not have culture confirmation
of TB
16 Had initial drug resistance
188 Were included in modified intention-
to-treat analysis
52 (22%) Were excluded
28 Were seen at end of follow-up
18 Had culture taken too early
1 Had missing culture result
9 Had contaminated culture
21 Did not complete follow-up
17 Were lost to follow-up
4 Died from non-TB causes
3 Had confirmed reinfection
on MIRU–VNTRS
212 Were included in modified intention-
to-treat analysis
39 (16%) Were excluded
17 Were seen at end of follow-up
10 Had culture taken too early
2 Had missing culture result
5 Had contaminated culture
20 Did not complete follow-up
9 Were lost to follow-up
5 Died from non-TB causes
6 Were withdrawn for pregnancy
2 Had confirmed reinfection
on MIRU–VNTRS
193 Were included in modified intention-
to-treat analysis
46 (19%) Were excluded
16 Were seen at end of follow-up
6 Had culture taken too early
1 Had missing culture result
7 Had contaminated culture
2 Did not produce sputum
26 Did not complete follow-up
16 Were lost to follow-up
8 Died from non-TB causes
2 Were withdrawn for pregnancy
4 Had confirmed reinfection
on MIRU–VNTRS
163 Were included in per-protocol
analysis
77 (32%) Were excluded
25 Were excluded because they did
not complete an adequate course
of treatment
186 Were included in per-protocol
analysis
65 (26%) Were excluded
26 Were excluded because they did
not complete an adequate course
of treatment
165 Were included in per-protocol
analysis
74 (31%) Were excluded
28 Were excluded because they did
not complete an adequate course
of treatment
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for the per-protocol analysis. The results are 
summarized in Figure 2. Kaplan–Meier esti-
mates of the time to unfavorable outcome analy-
sis for the per-protocol population are shown in 
Figure 3. With the 4-month regimen, 24 of 30 
unfavorable outcomes (80.0%) occurred less than 
6 months after the end of treatment, a finding 
that is consistent with that of other trials.23
There was no statistically significant interac-
tion between HIV status and treatment regimen 
in the per-protocol analysis or the modified in-
tention-to-treat analysis. The differences between 
regimens were consistent if all deaths or all re-
infections were classified as unfavorable (see Ta-
ble S1 in the Supplementary Appendix for these 
and other sensitivity analyses). A strict modified 
intention-to-treat analysis including all post-ran-
domization exclusions except for those determined 
late in screening indicated an increased benefit 
for patients receiving the 6-month regimen. How-
Characteristic
Control  
Regimen 
 (N = 188)
4-Month  
Regimen 
 (N = 193)
6-Month  
Regimen 
 (N = 212)
Total  
(N = 593)
Male sex — no. (%) 121 (64) 121 (63) 137 (65) 379 (64)
HIV-positive — no. (%) 54 (29) 55 (28) 49 (23) 158 (27)
Age — no. (%)
18–34 yr 115 (61) 132 (68) 127 (60) 374 (63)
35–54 yr 66 (35) 55 (28) 78 (37) 199 (34)
≥55 7 (4) 6 (3) 7 (3) 20 (3)
Weight — no. (%)
<40 kg 9 (5) 8 (4) 8 (4) 25 (4)
40–54 kg 103 (55) 100 (52) 120 (57) 323 (54)
55–69 kg 71 (38) 77 (40) 82 (39) 230 (39)
≥70 kg 5 (3) 8 (4) 2 (1) 15 (3)
Smoking status — no. (%)
Former smoker 47 (25) 46 (24) 47 (22) 140 (24)
Current smoker 46 (24) 51 (26) 64 (30) 161 (27)
Never smoked 95 (51) 96 (50) 101 (48) 292 (49)
Cavitation — no. (%)*
None 57 (33) 64 (35) 73 (37) 194 (35)
1–5 cm 86 (50) 85 (47) 91 (46) 262 (48)
>5 cm 30 (17) 32 (18) 33 (17) 95 (17)
CD4 cell count†
Median 355 317 298 314
Interquartile range 247– 455 256– 427 247– 383 253– 441
Days of previous tuberculosis treatment  
at randomization — no.
Median 5 4 4 4
Interquartile range 1–8 1–8 1–7 1–8
*  Radiographs obtained at baseline were not available for 42 patients. Between-group baseline characteristics were com-
pared by means of a chi-square test for independence for categorical variables and a nonparametric K-sample test of 
the equality of the medians for continuous variables. There were no statistically significant between-group differences in 
any of these baseline characteristics among the three treatment groups (P>0.1).
†  CD4 cell counts are based on counts from 158 patients coinfected with the human immunodeficiency virus (HIV).
Table 1. Baseline Characteristics of the Patients Included in the Modified Intention-to-Treat Analysis.
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Status and Outcome
Control  
Regimen
4-Month  
Regimen
6-Month  
Regimen Total
Per-protocol analysis — no. 163 165 186 514
Favorable — no. (%) 155 (95.1) 135 (81.8) 180 (96.8) 470 (91.4)
Unfavorable
Failure (culture confirmed) — no. 2 2 0 4
Death during treatment — no. 1 0 1 2
Relapse (culture confirmed) — no. 4 19 4 27
Relapse (limited bacteriology) — no. 1 7 1 9
Culture positive when last seen — no. 0 2 0 2
Total — no. (%) 8 (4.9) 30 (18.2) 6 (3.2) 44 (8.6)
Difference from control in unfavorable rate 
(adjusted for study center)
13.6 −1.8
90% CI 8.1 to 19.1 −6.1 to 2.4
95% CI 7.0 to 20.2 −6.9 to 3.3
Modified intention-to-treat analysis — no. 188 193 212 593
Favorable — no. (%) 161 (85.6) 141 (73.1) 183 (86.3) 485 (81.8)
Unfavorable
During treatment — no.
Failure (culture confirmed) 2 2 0 4
Death 1 0 1 2
Change in treatment due to adverse 
event
1 2 2 5
Lost to follow-up 5 6 8 19
Inadequate treatment 2 1 3 6
Other treatment change† 10 11 10 31
After treatment — no.
Relapse
Culture confirmation 4 19 4 27
Limited bacteriologic confirma-
tion‡
2 8 1 11
Death due to tuberculosis 0 1 0 1
Culture positive when last seen 0 2 0 2
Total — no. (%) 27 (14.4) 52 (26.9) 29 (13.7) 108 (18.2)
Difference from control in unfavorable rate 
(adjusted for study center)
13.1 0.4
90% CI (6.8 to 19.4) (−4.7 to 5.6)
95% CI (5.6 to 20.6) (−5.7 to 6.6)
*  CI denotes confidence interval.
†  Reasons for other treatment changes included poor adherence, withdrawal due to pregnancy after a positive culture, 
withdrawal of consent, and a move away from treatment center.
‡  Limited bacteriologic confirmation indicates that retreatment for relapse was initiated without confirmation on two pos-
itive cultures within 4 months after completion of treatment when no negative culture was obtained during the inter-
vening 4 months.
Table 2. Primary Outcome Classification According to Treatment Group for the Per-Protocol and Modified Intention-to-
Treat Analyses.*
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ever, this finding should be interpreted with cau-
tion, since fewer potential participants were ex-
cluded from this group, probably due to chance. 
Among 219 patients assessed at 2 months who 
received isoniazid for the first 2 months, 187 
(85.3%) had a negative culture as compared with 
394 of 436 patients (90.4%) who received moxi-
floxacin for the first 2 months (P = 0.06) (Table S2 
in the Supplementary Appendix).
Adherence to all three regimens was similar 
during the first 2 months of treatment. Thereaf-
ter, the proportions of patients with rates of ad-
herence that were 89% or higher were similar in 
all three groups (75.3% of patients receiving the 
control regimen, 81.4% of patients receiving the 
4-month regimen, and 80.9% of those receiving 
the 6-month regimen), but a smaller proportion 
of patients receiving the control regimen had ad-
herence rates of 95% or higher (48.7%, as com-
pared with 76.7% of those receiving the 4-month 
regimen and 76.9% of those receiving the 6-month 
regimen). The only instance of acquired resis-
tance to rifampicin occurred in a patient in the 
control group who was coinfected with HIV and 
did not adhere to the control regimen.
Safety
A total of 45 adverse events graded as severe or 
life threatening occurred in 38 patients during 
treatment (Table S3 in the Supplementary Appen-
dix), none of which were considered to have a 
definite relation to the study medication. How-
ever, 6 of the events in the control group, 6 of the 
events in the 4-month group, and 4 of the events 
in the 6-month group were considered to be pos-
sibly or probably related to the study medication. 
Among the 827 patients who underwent random-
ization, 25 patients died: 6 in the control group, 
12 in the group receiving the 4-month regimen, 
and 7 in the group receiving the 6-month regi-
men. Among these 25 deaths, 4 were classified 
as being possibly or probably related to tubercu-
losis (see details in Table S4 in the Supplemen-
tary Appendix). Among the 8 patients for whom 
the cause of death could not be ascertained, all 
had negative results on the last sputum specimen 
that was cultured. However, 6 of these patients 
were coinfected with HIV, and their deaths could 
have been HIV-related.
Discussion
This trial showed that a 6-month regimen with 
once-weekly dosing for the last 4 months was 
noninferior to the control regimen; no concerns 
related to safety were identified. In contrast, the 
4-month regimen, in which moxifloxacin and 
900 mg of rifapentine were administered twice 
weekly during the continuation phase, had a sig-
nificantly higher relapse rate than the control 
regimen. The selection of a 900-mg dose of rifa-
pentine for this regimen was based on the phar-
macokinetic–pharmacodynamic assumptions that 
the bactericidal effect was proportional to the area 
under the concentration curve (AUC), which sug-
gested that a regimen of 900 mg of rifapentine 
twice weekly would be more effective than a 
regimen of 1200 mg of rifapentine once weekly, 
and that the lower dose might reduce toxicity. 
Whereas studies in mice suggested that regimens 
shorter than the standard random were effec-
tive, this was not the case in our study.8,24 This 
discrepancy may be due to the presence of per-
sisting subpopulations of bacilli that are in a dor-
mant state in the lesions of pulmonary tubercu-
losis. These subpopulations of bacilli are thought 
to lead to relapse in humans,25 but they are largely 
absent in mice with experimentally induced tu-
berculosis. Because of these persisting subpopu-
lations, bactericidal efficacy may be related to peak 
rifapentine concentrations in human lesions but 
related to the AUC in the mice.26 Consequently, 
the administration of 900 mg of rifapentine twice 
weekly may not be more effective than the ad-
ministration of 1200 mg once weekly when 
Figure 2. Differences from the Control Regimen in  
Unfavorable Outcome Rates (90% Confidence Intervals).
The dashed line represents the 6 percentage-point 
margin of noninferiority for the modified intention- 
to-treat population and the per-protocol population  
as compared with the control.
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treating tuberculosis in humans, even when these 
regimens are of the same duration.
The substitution of moxifloxacin for isoniazid 
was proposed after a report of an acceleration in 
bacillary elimination after such a substitution was 
made in a study in mice.7 In our trial, this sub-
stitution reduced the proportion of patients with 
positive cultures at 2 months from 14.6% to 9.6%. 
This reduction compares with a decrease from 
45% to 40% in a phase 2 trial evaluating the same 
moxifloxacin substitution, albeit with a slightly 
different definition of end point.27 However, the 
exact role of moxifloxacin in helping to prevent 
relapse is uncertain. In a nested pharmacokinetic 
study, the results showed that although rifapen-
tine increased the clearance of moxifloxacin by 
8% during treatment as compared with clearance 
after treatment completion without rifapentine, 
it did not result in a clinically significant change 
in moxifloxacin exposure.28 More work is needed 
to determine whether the substitution of moxi-
floxacin for isoniazid was a necessary compo-
nent of the success of the once-weekly regimen of 
the continuation phase.
No acquired drug resistance was identified 
among patients receiving either of the intermit-
tent regimens, but the numbers were too small 
to provide any definitive conclusion. Nevertheless, 
the low relapse rate associated with the 6-month 
regimen suggests that acquired resistance is un-
likely to limit the usefulness of intermittent high 
dosing with rifapentine.
The trial had some limitations. The number 
of participants who underwent randomization 
(827) fell short of the target sample size (1095) 
due to a delayed start and slower-than-expected 
recruitment. However, the 827 participants were 
sufficient to interpret the results of both experi-
mental regimens. Only 27% of patients included 
in the modified intention-to-treat analysis were 
coinfected with HIV; their median CD4 cell count 
was 314 per cubic millimeter.3 Patients coinfected 
with HIV were therefore underrepresented, par-
ticularly those with low CD4 counts. Although 
the ingestion of drugs during the continuation 
phase in the control group was supervised by a 
person other than clinic staff, predefined require-
ments for adequate adherence to treatment did 
not differ according to treatment regimen.
Expanding the adoption of rapid tests such as 
the Xpert MTB/RIF to exclude rifampicin-resis-
tant disease would facilitate the safe use of the 
6-month regimen in resource-limited settings, 
making it possible to administer the regimen to 
patients with fully sensitive or mono-isoniazid-
resistant tuberculosis. The regimen is also par-
ticularly relevant for programs that rely on direct 
observation of daily treatment at health centers, 
since direct observation would be required only 
once weekly during the continuation phase and 
could therefore be delivered at a convenient loca-
tion. Replacing the current daily treatment ob-
servation required by the control regimen with a 
regimen in which the intensity of treatment ob-
servation is reduced could lower some health-sys-
tem costs, although the current costs of the drugs 
used in regimens requiring less observation are 
somewhat greater. No formal cost-effectiveness 
analysis was undertaken. However, Bayer has made 
a commitment to making moxifloxacin available 
at an affordable price,29 and recently Sanofi sub-
stantially reduced the cost of rifapentine in the 
United States.30 The meal of two boiled eggs and 
slices of bread provided to increase the absorp-
tion of rifapentine could be a barrier to implemen-
tation; further research is needed to determine to 
what extent this meal is necessary.
The 6-month regimen in which rifapentine and 
moxifloxacin are administered once weekly dur-
ing the continuation phase is noninferior to the 
standard regimen, which requires daily admin-
istration of medication for 6 months. The new 
Figure 3. Kaplan–Meier Failure Estimates of the Time to a Favorable  
Outcome in the Per-Protocol Population.
The inset shows the same data on an enlarged y axis.
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regimen could facilitate the strategy of directly 
observed treatment and could be used as first-
line treatment in certain settings, such as those 
with low rates of HIV coinfection or high rates 
of isoniazid resistance.
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